PRESS RELEASE
5 May 2025

Goodwin Welcomes Leading Life Sciences And Intellectual Property Partner William T. Christiansen II Ph.D.

GP
Goodwin Procter LLP

Contributor

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
Goodwin today announced that William (“Bill”) T. Christiansen II Ph.D. has joined the firm’s Life Sciences practice as a partner on the West Coast.
United States

Goodwin today announced that William (“Bill”) T. Christiansen II Ph.D. has joined the firm’s Life Sciences practice as a partner on the West Coast.

“Expanding our patent prosecution expertise is an important part of our strategy as our client base in the life sciences sector continues to grow at pace,” said Mitchell Bloom, Global Chair of Goodwin’s Life Sciences Practice. “As a team, we are committed to providing end-to-end support for biotechnology, pharmaceutical, and medical technology companies throughout their growth journey. Bill’s impressive track record and his unwavering commitment to excellence aligns perfectly with our firm's values and will help bolster our intellectual property capabilities to serve companies across all development stages."

Bill advises biotechnology, pharmaceutical, and medical device companies, as well as universities, non-profit research institutions, and investors on intellectual property and market exclusivity strategies. He specializes in patent procurement, portfolio management, investment due diligence, early-stage company counseling, competitive patent analysis, and IP value creation.

He also has experience supporting litigation teams with technical and patent issues as well as providing counsel to both national and international clients regarding freedom to operate opinions, invalidity and non-infringement opinions, due diligence transactions, oppositions, and re-examination proceedings. His extensive knowledge of the industry covers diverse technologies including therapeutics, immunology, gene therapy, diagnostics, vaccines, and bioinformatics.

In addition to Bill, Goodwin also recently added intellectual property partner Carl Morales in New York earlier this year.

With more than 240 dedicated lawyers and patent agents across all major life sciences hubs in the US, Europe, and Asia, Goodwin works with life sciences companies throughout the corporate lifecycle – from startup and commercial-stage to maturity – as well as investors, banks, and others in the life sciences ecosystem. The firm understands the unique challenges life sciences companies face in securing funding, licensing and safeguarding intellectual property, establishing partnerships, bringing new products to market, opening new revenue streams, and protecting existing product lines. The team takes a multidisciplinary approach to address clients’ challenges, drawing on deep expertise across industries – such as technology, healthcare, real estate, and private equity – as well as the full spectrum of relevant practices. Goodwin was recently shortlisted by Managing IP for Firm of the Year – Patent Prosecution and Life Sciences IP Litigation. You can read more about the news here.

Contributor

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More